Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethnic Differences in Dupilumab Mechanisms for Atopic Dermatitis
NCT05268107Phase 4Recruiting
- Sponsor
- University of Michigan
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of dupilumab in atopic dermatitis (AD), sponsored by University of Michigan. Primary endpoint: Change in expression of interleukin 4 at 2 weeks. Started Jan 2023; status: recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05268107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268107.